# Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02175342** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 202 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium 0.625 mcg/puff
- **DRUG:** Tiotropium 1.25 mcg/puff
- **DRUG:** Tiotropium 2.5 mcg/puff
- **DRUG:** Tiotropium 5 mcg/puff
- **DRUG:** Placebo solution
- **DRUG:** Tiotropium-18 lactose powder
- **DRUG:** Placebo lactose powder
- **DRUG:** Tiotropium 10 mcg/puff
- **DEVICE:** Respimat
- **DEVICE:** Handihaler

## Key facts

- **NCT ID:** NCT02175342
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03-01
- **Primary completion:** 1999-04-01
- **Final completion:** —
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175342, "Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02175342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*